Altered GABAB receptor immunoreactivity in the gerbil hippocampus induced by baclofen and phaclofen, not seizure activity

Neurosci Res. 2004 Aug;49(4):405-16. doi: 10.1016/j.neures.2004.05.004.

Abstract

The present study was performed to determine whether the effects induced by GABA(B) receptor-acting drugs would be related with the alteration in GABA(B) receptor expression in the hippocampus using Mongolian gerbil, a genetic epilepsy model. The distribution patterns of both GABA(B) receptor 1A/B and GABA(B)receptor 2 immunoreactivities were similarly detected in the hippocampi of normal and seizure-prone gerbils. Following baclofen (GABA(B) receptor agonist) or phaclofen (GABA(B) receptor antagonist) treatment, GABA(B) receptor immunoreactivities were decreased or increased by dose-dependent manners, respectively. Vigabatrin (GABA transaminase inhibitor) or 3-mercaptopropionic acid (GAD inhibitor) treatment did not affect GABA(B) receptor expressions. These findings suggest that GABA(B) receptor expression in the gerbil hippocampus may be altered by baclofen or phaclofen treatment.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Baclofen / analogs & derivatives*
  • Baclofen / pharmacology*
  • Blotting, Western / methods
  • Cell Count
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • GABA Antagonists / pharmacology*
  • Gene Expression Regulation / drug effects
  • Gerbillinae
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Immunohistochemistry / methods
  • Proline / analogs & derivatives*
  • Proline / pharmacology
  • Receptors, GABA-B / metabolism*
  • Vigabatrin / pharmacology

Substances

  • 3-mercaptoproline
  • Enzyme Inhibitors
  • GABA Antagonists
  • Receptors, GABA-B
  • phaclofen
  • Proline
  • Vigabatrin
  • Baclofen